Table 1.

Patients' characteristics

	Patients	Controls
Number	51	41
female:male	35:16	22:19
PAH	41
Idiopathic/ hereditary PAH	29
Collagen-vascular diseases	7
Congenital heart diseases	5
CTEPH	10
PH target therapy*
Endothelin-receptor-antagonists	44
Phosphodiesterase-5-inhibitors	22
Prostacyclines**	9

^*Several patients are treated with combination therapy.

^**Intravenous epoprostenol (two patients), inhalative iloprost (four patients), subcutaneous treprostinil (three patients).